AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer / Endpoints

Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...

#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment

Nelson Dusetti: Why Oncogenic KRAS Alone Is Not Sufficient to Drive Pancreatic Cancer?

2 months / oncodaily

BridgeBio shares KRAS data; Hutchmed's Phase 3 success in China

2 months / endpoints / ENDPOINTS

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial

2 months / nature / Benjamin L. Musher

Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blocker

2 months / endpoints / Ayisha Sharma

Naoto T. Ueno: Breakthrough Advances in K-RAS Inhibitor Development

2 months / oncodaily

Jacobio Pharma and AstraZeneca Strike $2 B Deal for Pan‑KRAS Inhibitor

2 months / oncodaily

AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer

2 months / endpoints / Ayisha Sharma

Saturday, December 27, 2025, 6:20 am / permalink 17306 / 7 stories in 2 months

Related Stories

Novartis pays $100M upfront for macrocyclic peptide platform / 18 days
Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 25 days
Servier to acquire Day One Biopharma for $2.5B / 4 days
Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 9 days
Eli Lilly buys Orna to sprint into in‑vivo CAR‑T therapeutics / 25 days
Merck Eyes $30B Deal for Revolution Medicines Acquisition / 1 month
Merck acquires Cidara’s preventive flu drug for $9.2B / 3 months

Related Tags

Pharmaceuticals

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

more #pharmaceuticals

Biotech

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

Cancer Grand Challenges awards five teams bold funding for cancer research (3 days)

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes (4 days)

Mergers and Acquisitions

MUSC Health buys large South Carolina multispecialty practice for $111M (2 days)

Servier to acquire Day One Biopharma for $2.5B (4 days)

Novartis closes Avidity deal; Atrium Therapeutics spinout launches (9 days)

more #mergersandacquisitions

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.